Toboroz
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189· 3. fázis· Corbus Pharmaceuticals Inc.· Forrás
Contact: Clinical Study Coordinator
Toboroz
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Contact: Communication Center
Toboroz
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
NCT07252726· 4. fázis· Ottawa Hospital Research Institute· Forrás
Contact: Lauren Butterfield, MSc
Még nem toboroz
FMT in Triple Negative Breast Cancer Guided by ctDNA
NCT07292142· 1/2. fázis· Jewish General Hospital· Forrás
Contact: Terry L Ng, MD
Toboroz
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· 3. fázis· ArriVent BioPharma, Inc.· Forrás
Contact: Clinical Trials
Toboroz
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448· 2. fázis· Ono Pharmaceutical Co., Ltd.· Forrás
Contact: North America Clinical Trial Support Desk
Toboroz
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762· 2/3. fázis· Bristol-Myers Squibb· Forrás
Contact: Christina Canil, Site 0021
Toboroz
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· 3. fázis· Relay Therapeutics, Inc.· Forrás
Contact: Relay Therapeutics, Inc
Toboroz
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· 3. fázis· Pfizer· Forrás
Toboroz
The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma
NCT06850766· Ottawa Hospital Research Institute· Forrás
Contact: Lisa Vandermeer, MSc
Toboroz
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Fut, nem toboroz
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563· 3. fázis· NovoCure GmbH· Forrás
Toboroz
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025· 2/3. fázis· Daiichi Sankyo· Forrás
Toboroz
Dose Escalation For INtraprostatic LEsions
NCT05851547· 2. fázis· Ottawa Hospital Research Institute· Forrás
Contact: Scott Grimes
Toboroz
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036· 3. fázis· Regeneron Pharmaceuticals· Forrás
Contact: Clinical Trials Administrator
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211· 3. fázis· Gilead Sciences· Forrás
Toboroz
THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM)
NCT05326334· Ottawa Hospital Research Institute· Forrás
Contact: Terry L. Ng, MD
Fut, nem toboroz
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530· 2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Fut, nem toboroz
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT05464030· 1. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Toboroz
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05379595· 1/2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717· 3. fázis· Amgen· Forrás
Fut, nem toboroz
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378· 2. fázis· BioNTech SE· Forrás
Fut, nem toboroz
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
NCT04549207· 4. fázis· Ottawa Hospital Research Institute· Forrás
Fut, nem toboroz
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
NCT04421820· 1/2. fázis· Bold Therapeutics, Inc.· Forrás
Contact: Saara Ali
Fut, nem toboroz
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
NCT04065269· 2. fázis· Institute of Cancer Research, United Kingdom· Forrás
Toboroz
Study Looking at Biomarkers in Ovarian Cancer
NCT03419689· University Health Network, Toronto· Forrás
Contact: Johanne Weberpals, M.D.
Toboroz
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
NCT02906943· University Health Network, Toronto· Forrás
Contact: Han (Jenny) Zhang
Fut, nem toboroz
Preoperative vs Postoperative IMRT for Extremity/Truncal STS
NCT02565498· 3. fázis· Mount Sinai Hospital, Canada· Forrás
Fut, nem toboroz
Prostate Advances in Comparative Evidence
NCT01584258· 3. fázis· Royal Marsden NHS Foundation Trust· Forrás